Insider Transactions Reported by 26 Insiders of Cartesian Therapeutics, Inc.

Symbol: RNAC on Nasdaq
Location: Frederick, MD

Quick Takeaways

RNAC - Cartesian Therapeutics, Inc. has 26 insiders with reported activity on this page.
Net insider value flow over the last year: +$407,654.
Recent transaction rows are available for direct filing-level review.

What Changed

Buy value: $666,326; sell value: $258,671.
Net share flow: +34,820.

Why This Matters

This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.

Official SEC Source

Filed on Form 4

Issuer insider activity is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Insider trading overview

Last 12 months

Net insider flow leans to buying over the last 12 months. Net value: +$407,654.

Buys

$666,326

Shares: 72,750

Insiders: 2

Sells

$258,671

Shares: 37,930

Insiders: 3

Net

+$407,654

Shares: +34,820

Insiders: -1

Window (months)	Buy shares	Sell shares	Buy $	Sell $	Net $
0-3	0	0	$0	$0	$0
3-6	30,000	37,930	$205,797	$258,671	-$52,874
6-9	0	0	$0	$0	$0
9-12	42,750	0	$460,529	$0	+$460,529

Cartesian Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name	Relationship	Holdings Value	Past Year Net Change	Change %	Valuation	Report Date
Timothy A. Springer	Director, 10%+ Owner	$81,409,176			Mixed	02 Jan 2026
Murat Kalayoglu	10%+ Owner	$41,970,235			Mixed	02 Apr 2026
Seven One Eight Three Four Irrevocable Trust	10%+ Owner	$41,964,073			Mixed	02 Apr 2026
Elizabeth Hoge	10%+ Owner	$41,964,073			Mixed	02 Apr 2026
Carsten Brunn	President and CEO, Director	$2,206,377	-$162,077	-6.8%	Filing P/S	06 Jan 2026
Metin Kurtoglu	Chief Technology Officer	$1,110,427			Mixed	03 Jan 2025
Michael Singer	Director	$1,081,194			Mixed	13 Mar 2026
Peter G. Traber	Chief Medical Officer	$930,762			Mixed	25 Sep 2023
Lloyd P. Johnston	Chief Operations Officer	$922,211			Mixed	04 Jan 2023
Emily English	Chief Operations Officer	$835,211			Mixed	02 Jan 2026
Blaine Davis	Chief Financial Officer	$826,684	-$72,227	-8%	Filing P/S	06 Jan 2026
Aymeric Sallin	Director	$546,800			Mixed	02 Jan 2024
Timothy C. Barabe	Director	$487,524	+$205,797	+73%	Mixed	02 Jan 2026
Takashi Kei Kishimoto	Chief Scientific Officer	$464,151			Mixed	30 May 2023
Kevin Tan	Chief Financial Officer	$427,220			Mixed	03 Jan 2022
Milos Miljkovic	Chief Medical Officer	$401,134	-$24,367	-5.7%	Filing P/S	06 Jan 2026
Christopher M. Jewell	Chief Scientific Officer	$255,114			Mixed	10 Jan 2025
ZENNER PATRICK J	Director	$115,792			Mixed	02 Jan 2026
Nishan M. DeSilva	Director	$102,204			Mixed	02 Jan 2026
Kemal Malik	Director	$100,235			Mixed	02 Jan 2026
Goran Ando	Director	$59,250			Mixed	02 Jan 2023
Carrie S. Cox	Director	$57,896			Mixed	02 Jan 2025
June Ann Seymour	Chief Accounting Officer	$54,925			Mixed	02 Jan 2026
Adrian Ion Bot	Director	$44,080			Mixed	16 Dec 2025
Ann K. Donohue	VP Finance	$8,625			Mixed	27 May 2021
Scott Dunseth Myers	Director				Mixed	13 Nov 2023

Top shareholders of Cartesian Therapeutics, Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Timothy A. Springer	13D/G 3/4/5	Director, 10%+ Owner	37%	9,555,394	$116,671,361	+$258,583	13 Jan 2025	13D/G 3/4/5
Murat Kalayoglu	13D/G 3/4/5	10%+ Owner	20%	5,833,971	$48,188,600	$0	31 Mar 2026	13D/G 3/4/5
Elizabeth Hoge	3/4/5	10%+ Owner	— mixed-class rows	5,853,922 mixed-class rows	$41,964,073	—	02 Apr 2026	3/4/5
Seven One Eight Three Four Irrevocable Trust	3/4/5	10%+ Owner	— mixed-class rows	5,853,922 mixed-class rows	$41,964,073	—	02 Apr 2026	3/4/5
JPMORGAN CHASE & CO	13D/G 13F	Company	6.1%	1,675,636	$20,459,516	$0	31 Mar 2025	13D/G 13F
Squarepoint Ops LLC	13D/G 13F	Company	8.3%	2,209,601	$14,163,542	$0	09 Mar 2026	13D/G 13F
FMR LLC	13D/G 13F	Company	5.3%	1,366,989	$9,869,661	-$5,695,093	31 Dec 2025	13D/G 13F
BlackRock, Inc.	13F	Company	2.1%	609,696	$4,395,908	—	31 Dec 2025	13F
VANGUARD GROUP INC	13F	Company	1.8%	541,228	$3,902,253	—	31 Dec 2025	13F
Carsten Brunn	3/4/5	President and CEO, Director	— mixed-class rows	739,230 mixed-class rows	$2,206,377	-$162,077	06 Jan 2026	3/4/5
683 Capital Management, LLC	13F	Company	0.96%	280,000	$2,018,800	—	31 Dec 2025	13F
Erste Asset Management GmbH	13F	Company	0.93%	271,705	$1,956,354	—	31 Dec 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.87%	255,539	$1,842,696	—	31 Dec 2025	13F
STATE STREET CORP	13F	Company	0.68%	198,967	$1,434,552	—	31 Dec 2025	13F
MARSHALL WACE, LLP	13F	Company	0.61%	178,140	$1,284,388	—	31 Dec 2025	13F
Privium Fund Management B.V.	13F	Company	0.59%	172,500	$1,243,725	—	31 Dec 2025	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.56%	164,366	$1,185,079	—	31 Dec 2025	13F
Metin Kurtoglu	3/4/5	Chief Technology Officer	— mixed-class rows	188,757 mixed-class rows	$1,110,427	—	03 Jan 2025	3/4/5
Michael Singer	3/4/5	Director	— mixed-class rows	175,512 mixed-class rows	$1,081,194	—	13 Mar 2026	3/4/5
Peter G. Traber	3/4/5	Chief Medical Officer	— class O/S missing	451,826	$930,762	—	25 Sep 2023	3/4/5
Lloyd P. Johnston	3/4/5	Chief Operations Officer	— mixed-class rows	740,515 mixed-class rows	$922,211	—	04 Jan 2023	3/4/5
Emily English	3/4/5	Chief Operations Officer	— mixed-class rows	184,595 mixed-class rows	$835,211	—	02 Jan 2026	3/4/5
Blaine Davis	3/4/5	Chief Financial Officer	— mixed-class rows	230,220 mixed-class rows	$826,684	-$72,227	06 Jan 2026	3/4/5
BANK OF AMERICA CORP /DE/	13F	Company	0.39%	113,092	$815,393	—	31 Dec 2025	13F
JACOBS LEVY EQUITY MANAGEMENT, INC	13F	Company	0.33%	95,799	$690,711	—	31 Dec 2025	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.31%	91,278	$658,114	—	31 Dec 2025	13F
NORTHERN TRUST CORP	13F	Company	0.3%	87,013	$627,364	—	31 Dec 2025	13F
CITADEL ADVISORS LLC	13F	Company	0.27%	79,785	$575,250	—	31 Dec 2025	13F
GSA CAPITAL PARTNERS LLP	13F	Company	0.26%	77,227	$557,000	—	31 Dec 2025	13F
Aymeric Sallin	3/4/5	Director	— mixed-class rows	406,000 mixed-class rows	$546,800	—	02 Jan 2024	3/4/5
Timothy C. Barabe	3/4/5	Director	— mixed-class rows	64,766 mixed-class rows	$487,524	+$205,797	02 Jan 2026	3/4/5
UBS Group AG	13F	Company	0.23%	67,341	$485,528	—	31 Dec 2025	13F
Takashi Kei Kishimoto	3/4/5	Chief Scientific Officer	— class O/S missing	225,316	$464,151	—	30 May 2023	3/4/5
Kevin Tan	3/4/5	Chief Financial Officer	— mixed-class rows	417,000 mixed-class rows	$427,220	—	03 Jan 2022	3/4/5
Milos Miljkovic	3/4/5	Chief Medical Officer	— mixed-class rows	135,820 mixed-class rows	$401,134	-$24,367	06 Jan 2026	3/4/5
Walleye Capital LLC	13F	Company	0.15%	43,878	$316,360	—	31 Dec 2025	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.14%	41,100	$296,331	—	31 Dec 2025	13F
Christopher M. Jewell	3/4/5	Chief Scientific Officer	— mixed-class rows	177,322 mixed-class rows	$255,114	—	10 Jan 2025	3/4/5
Point72 Asset Management, L.P.	13F	Company	0.12%	33,871	$244,207	—	31 Dec 2025	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.09%	25,300	$182,413	—	31 Dec 2025	13F
Bank of New York Mellon Corp	13F	Company	0.09%	25,241	$181,988	—	31 Dec 2025	13F
BRIDGEWAY CAPITAL MANAGEMENT, LLC	13F	Company	0.09%	25,000	$180,250	—	31 Dec 2025	13F
TWO SIGMA ADVISERS, LP	13F	Company	0.08%	24,808	$178,866	—	31 Dec 2025	13F
Nuveen, LLC	13F	Company	0.08%	24,497	$176,623	—	31 Dec 2025	13F
MORGAN STANLEY	13F	Company	0.08%	23,294	$167,950	—	31 Dec 2025	13F
Ikarian Capital, LLC	13F	Company	0.07%	20,807	$150,018	—	31 Dec 2025	13F
AMERIPRISE FINANCIAL INC	13F	Company	0.07%	19,806	$142,801	—	31 Dec 2025	13F
TWIN FOCUS CAPITAL PARTNERS, LLC	13F	Company	0.07%	19,500	$140,595	—	31 Dec 2025	13F
BARCLAYS PLC	13F	Company	0.06%	17,651	$127,264	—	31 Dec 2025	13F
Jain Global LLC	13F	Company	0.06%	16,724	$120,580	—	31 Dec 2025	13F

Recent Insider Transactions by Companies or Individuals for Cartesian Therapeutics, Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	%	Value $	* Price $	Shares	Shares Owned	Date	Ownership
Hoge Elizabeth	RNAC	Common Stock	Options Exercise	16.6%			758,001	5,313,261	02 Apr 2026	as trustee
Elizabeth Hoge	RNAC	Common Stock	Options Exercise	16.6%			758,001	5,313,261	02 Apr 2026	as trustee
Hoge Elizabeth	RNAC	Series A Non-Voting Convertible Preferred Stock	Options Exercise	-40.3%			-22,740	33,662	02 Apr 2026	as trustee
Elizabeth Hoge	RNAC	Series A Non-Voting Convertible Preferred Stock	Options Exercise	-40.3%			-22,740	33,662	02 Apr 2026	as trustee
Murat Kalayoglu	RNAC	Common Stock	Options Exercise	16.6%			758,001	5,313,261	02 Apr 2026	by trust
Murat Kalayoglu	RNAC	Series A Non-Voting Convertible Preferred Stock	Options Exercise	-40.3%			-22,740	33,662	02 Apr 2026	by trust
Michael Singer	RNAC	Common Stock	Gift	-11.7%			-6,555	49,578	13 Mar 2026	Direct
Carsten Brunn	RNAC	Common Stock	Sale	-6.84%	$162,077	$6.82	-23,766	323,530	06 Jan 2026	Direct
Milos Miljkovic	RNAC	Common Stock	Sale	-5.73%	$24,367	$6.82	-3,573	58,820	06 Jan 2026	Direct
Blaine Davis	RNAC	Common Stock	Sale	-8.03%	$72,227	$6.82	-10,591	121,220	06 Jan 2026	Direct
Nishan M. DeSilva	RNAC	Common Stock	Award	29.7%			2,600	11,366	02 Jan 2026	Direct
Nishan M. DeSilva	RNAC	Stock Option (Right to Buy)	Award				7,800	7,800	02 Jan 2026	Direct
Carsten Brunn	RNAC	Common Stock	Award	70.2%			143,200	347,296	02 Jan 2026	Direct
Carsten Brunn	RNAC	Employee Stock Option (right to buy)	Award				415,700	415,700	02 Jan 2026	Direct
Kemal Malik	RNAC	Common Stock	Award	30.5%			2,600	11,133	02 Jan 2026	Direct
Kemal Malik	RNAC	Stock Option (Right to Buy)	Award				7,800	7,800	02 Jan 2026	Direct
Milos Miljkovic	RNAC	Common Stock	Award	76.3%			27,000	62,393	02 Jan 2026	Direct
Milos Miljkovic	RNAC	Employee Stock Option (right to buy)	Award				77,000	77,000	02 Jan 2026	Direct
Zenner Patrick J	RNAC	Common Stock	Award	25.1%			2,600	12,974	02 Jan 2026	Direct
Zenner Patrick J	RNAC	Stock Option (Right to Buy)	Award				7,800	7,800	02 Jan 2026	Direct
June Ann Seymour	RNAC	Common Stock	Award				6,500	6,500	02 Jan 2026	Direct
June Ann Seymour	RNAC	Employee Stock Option (right to buy)	Award				19,000	19,000	02 Jan 2026	Direct
Blaine Davis	RNAC	Common Stock	Award	39%			37,000	131,811	02 Jan 2026	Direct
Blaine Davis	RNAC	Employee Stock Option (right to buy)	Award				109,000	109,000	02 Jan 2026	Direct
Timothy C. Barabe	RNAC	Common Stock	Award	4.78%			2,600	56,966	02 Jan 2026	Direct
Timothy C. Barabe	RNAC	Stock Option (Right to Buy)	Award				7,800	7,800	02 Jan 2026	Direct
Emily English	RNAC	Common Stock	Award	34.2%			24,000	94,226	02 Jan 2026	Direct
Emily English	RNAC	Employee Stock Option (right to buy)	Award				71,000	71,000	02 Jan 2026	Direct
Michael Singer	RNAC	Common Stock	Award	4.86%			2,600	56,133	02 Jan 2026	Direct
Michael Singer	RNAC	Stock Option (Right to Buy)	Award				7,800	7,800	02 Jan 2026	Direct
Timothy A. Springer	RNAC	Common Stock	Award	0.03%			2,600	8,646,285	02 Jan 2026	Direct
Timothy A. Springer	RNAC	Stock Option (Right to Buy)	Award				7,800	7,800	02 Jan 2026	Direct
Murat Kalayoglu	RNAC	Common Stock	Award	0.51%			2,600	511,577	02 Jan 2026	Direct
Murat Kalayoglu	RNAC	Stock Option (Right to Buy)	Award				7,800	7,800	02 Jan 2026	Direct
Emily English	RNAC	Common Stock	Options Exercise	12%			7,500	70,226	30 Dec 2025	Direct
Emily English	RNAC	Stock Option (Right to Buy)	Options Exercise	-27.9%			-7,500	19,369	30 Dec 2025	Direct
Adrian Ion Bot	RNAC	Common Stock	Award				5,800	5,800	16 Dec 2025	Direct
Adrian Ion Bot	RNAC	Stock Option (Right to Buy)	Award				17,200	17,200	16 Dec 2025	Direct
Timothy C. Barabe	RNAC	Common Stock	Purchase	123.1%	$205,797	$6.86	30,000	54,366	04 Dec 2025	Direct
Emily English	RNAC	Common Stock	Options Exercise	13.6%			7,500	62,726	28 Nov 2025	Direct
Emily English	RNAC	Stock Option (Right to Buy)	Options Exercise	-21.8%			-7,500	26,869	28 Nov 2025	Direct
Michael Singer	RNAC	Common Stock	Gift	-27.2%			-20,000	53,533	18 Nov 2025	Direct
June Ann Seymour	RNAC	Employee Stock Option (right to buy)	Award				50,000	50,000	27 Oct 2025	Direct
Emily English	RNAC	Common Stock	Options Exercise	15.7%			7,500	55,226	12 May 2025	Direct
Emily English	RNAC	Stock Option (Right to Buy)	Options Exercise	-17.9%			-7,500	34,369	12 May 2025	Direct
Emily English	RNAC	Common Stock	Options Exercise	18.6%			7,500	47,726	15 Apr 2025	Direct
Emily English	RNAC	Stock Option (Right to Buy)	Options Exercise	-15.2%			-7,500	41,869	15 Apr 2025	Direct
Timothy A. Springer	RNAC	Common Stock	Purchase	5.86%	$391,455	$10.77	36,338	656,513	11 Apr 2025	See Footnote
Timothy A. Springer	RNAC	Common Stock	Purchase	0.07%	$69,074	$10.77	6,412	8,643,685	11 Apr 2025	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.